Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcello Deraco

Showing results (131-140 of 178) with videos related to

Pageof 18
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 10, 2010
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesotheliomaFederica Perrone, Genny Jocollè, Marzia Pennati, et al.
Updates in Surgery|April 10, 2026
Communication skill training in surgical residency: insights from Y-SICO (Young-Italian Society of Surgical Oncology)Rossella Melcarne, Federico Cappellacci, Filippo Carannante, et al.
International Journal of Molecular Sciences|July 11, 2020
A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian CancerStefano Guadagni, Marco Clementi, Francesco Masedu, et al.
Journal of Immunology Research|December 5, 2018
Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological TypesMarcella Tazzari, Silvia Brich, Alessandra Tuccitto, et al.
Annals of Surgical Oncology|December 21, 2017
Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International RegistryKonstantinos I Votanopoulos, Paul Sugarbaker, Marcello Deraco, et al.
Cancers|February 11, 2023
Diagnostic and Therapeutic Algorithm for Appendiceal Tumors and Pseudomyxoma Peritonei: A Consensus of the Peritoneal Malignancies Oncoteam of the Italian Society of Surgical Oncology (SICO)Marco Vaira, Manuela Robella, Marcello Guaglio, et al.
Clinical Colorectal Cancer|April 27, 2019
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma PeritoneiAlessandra Raimondi, Salvatore Corallo, Monica Niger, et al.
International Journal of Molecular Sciences|November 23, 2019
Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal MesotheliomaAntonino Belfiore, Adele Busico, Fabio Bozzi, et al.
Cancer Gene Therapy|March 30, 2022
miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesotheliomaRihan El Bezawy, Stefano Percio, Chiara Maura Ciniselli, et al.
Cancers|December 11, 2022
Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results AnalysisFabio Carboni, Mario Valle, Marco Vaira, et al.
Pageof 18

Showing results (131-140 of 178) with videos related to

Sort By:
Pageof 18
European Journal of Cancer (Oxford, England : 1990)|August 10, 2010
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesotheliomaFederica Perrone, Genny Jocollè, Marzia Pennati, et al.
Updates in Surgery|April 10, 2026
Communication skill training in surgical residency: insights from Y-SICO (Young-Italian Society of Surgical Oncology)Rossella Melcarne, Federico Cappellacci, Filippo Carannante, et al.
International Journal of Molecular Sciences|July 11, 2020
A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian CancerStefano Guadagni, Marco Clementi, Francesco Masedu, et al.
Journal of Immunology Research|December 5, 2018
Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological TypesMarcella Tazzari, Silvia Brich, Alessandra Tuccitto, et al.
Annals of Surgical Oncology|December 21, 2017
Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International RegistryKonstantinos I Votanopoulos, Paul Sugarbaker, Marcello Deraco, et al.
Cancers|February 11, 2023
Diagnostic and Therapeutic Algorithm for Appendiceal Tumors and Pseudomyxoma Peritonei: A Consensus of the Peritoneal Malignancies Oncoteam of the Italian Society of Surgical Oncology (SICO)Marco Vaira, Manuela Robella, Marcello Guaglio, et al.
Clinical Colorectal Cancer|April 27, 2019
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma PeritoneiAlessandra Raimondi, Salvatore Corallo, Monica Niger, et al.
International Journal of Molecular Sciences|November 23, 2019
Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal MesotheliomaAntonino Belfiore, Adele Busico, Fabio Bozzi, et al.
Cancer Gene Therapy|March 30, 2022
miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesotheliomaRihan El Bezawy, Stefano Percio, Chiara Maura Ciniselli, et al.
Cancers|December 11, 2022
Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results AnalysisFabio Carboni, Mario Valle, Marco Vaira, et al.
Pageof 18